Stiffer Spleen Predicts Higher Bone Marrow Fibrosis and Higher JAK2 Allele Burden in Patients With Myeloproliferative Neoplasms

被引：5
|
作者：
Moia, Riccardo [1 ,2 ]
Cittone, Micol Giulia [2 ,3 ]
Boggione, Paola [1 ,2 ]
Manfredi, Giulia Francesca [2 ,3 ]
Favini, Chiara [1 ,2 ]
Awikeh, Bassel [1 ,2 ]
Pedrinelli, Anita Rebecca [2 ,3 ]
Mahmoud, Abdurraouf Mokhtar [1 ,2 ]
Nicolosi, Maura [1 ,2 ]
Bellan, Mattia [2 ,3 ]
Sainaghi, Pier Paolo [2 ,3 ]
Pirisi, Mario [2 ,3 ]
Gaidano, Gianluca [1 ,2 ]
Patriarca, Andrea [1 ,2 ]
Rigamonti, Cristina [2 ,3 ]
机构：
[1] Univ Piemonte Orientale, Dept Translat Med, Div Hematol, Novara, Italy
[2] Azienda Osped Univ Maggiore Carita, Novara, Italy
[3] Univ Piemonte Orientale, Dept Translat Med, Div Internal Med, Novara, Italy
来源：
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词：
myeloproliferative neoplasms; spleen stiffness; JAK2; mutations; vibration-controlled transient elastography (VCTE); NGS; TRANSIENT ELASTOGRAPHY; PORTAL-HYPERTENSION; STIFFNESS; LIVER;
D O I：
10.3389/fonc.2021.777730
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A total of 63 myeloproliferative neoplasms [MPN; 9 polycythemia vera (PV), 32 essential thrombocythemia (ET), and 22 myelofibrosis (MF)] underwent spleen stiffness (SS) measurement by vibration-controlled transient elastography equipped with a novel spleen-dedicated module. Higher SS values significantly correlated with grade 2-3 bone marrow (BM) fibrosis (p=0.035), with hemoglobin level <10 g/dl (p=0.014) and with white blood cells >= 10,000/mu l (p=0.008). Median SS was significantly higher in MF patients compared to ET and PV (p=0.015). SS also correlated with higher JAK2 variant allele frequency (p=0.02). This study identifies SS as a potential noninvasive tool that reflects BM fibrosis and the mutational burden in MPN.
引用
收藏
页数：5
相关论文
共 50 条
  • [21] JAK2 V617F Allele Burden in Non-CML Classical Subtypes of Myeloproliferative Neoplasms (MPN)
    Gober-Wilcox, J.
    Vennapusa, B.
    Pierce, J.
    Vasef, M. A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2008, 10 (06): : 581 - 581
  • [22] JAK2 V617F Mutation Allele Burden (MAB) and Its Correlation with Hematologic Characteristics in Myeloproliferative Neoplasms
    Kim, David Y.
    Tariq, Hamza
    Brown, Alan F.
    Vadlamudi, Kumari
    Wang, Yao
    Ikoma, Shohei
    Holder, Kenneth N.
    Higgins, Russell A.
    Fan, Hongxin
    BLOOD, 2017, 130
  • [23] JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
    Ma, Wanlong
    Kantarjian, Hagop
    Zhang, Xi
    Wang, Xiuqiang
    Zhang, Zhong
    Yeh, Chen-Hsiung
    O'Brien, Susan
    Giles, Francis
    Bruey, Jean Marie
    Albitar, Maher
    PLOS ONE, 2010, 5 (08):
  • [24] CALR, JAK2 Exon 14, and JAK2 Exon 12 mutations profiles in patients with Myeloproliferative Neoplasms
    Yasin, Elrashed B.
    Alkhatabi, Heba
    Ahmedah, Hanadi Talal
    Felimban, Raed
    Tayeb, Hossam H.
    Alalla, Zainab Jawdat
    Abdulqayoom, Heyam Abdulsamad
    Alserihi, Raed
    BIOSCIENCE RESEARCH, 2021, 18 (02): : 1699 - 1707
  • [25] The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases
    Aktimur, Sude H.
    Malkan, Umit Y.
    Eyupoglu, Damla N.
    Haznedaroglu, Ibrahim C.
    Kelkitli, Engin
    Atay, Hilmi M.
    Gunes, Gursel
    Etgul, Sezgin
    Aslan, Tuncay
    Goker, Hakan
    Sayinalp, Nilgun
    Aksu, Salih
    Ozcebe, Osman I.
    Buyukasik, Yahya
    Turgut, Mehmet
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2016, 26 (03): : 153 - 158
  • [26] The morphometric characteristic of bone marrow megakaryocyte clusters in Ph-negative JAK2 mutated chronic myeloproliferative neoplasms
    Krivolapov, Y.
    Asaulenko, Z.
    Spiridonov, I.
    Selent'eva, A.
    Polushkina, L.
    VIRCHOWS ARCHIV, 2018, 473 : S100 - S100
  • [27] HIGH SENSITIVITY MLPA ASSAY FOR THE DETECTION OF THE RECURRENT CALR, JAK2, KIT AND MPL MUTATIONS WITH ≥1% ALLELE BURDEN IN MYELOPROLIFERATIVE NEOPLASMS
    Steenkamer, M.
    Stuitje, A.
    Atanesyan, L.
    Stouten, K.
    van de Werken, M.
    Castel, R.
    Savola, S.
    HAEMATOLOGICA, 2016, 101 : 806 - 806
  • [28] JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms
    Shirane, Shuichi
    Araki, Marito
    Morishita, Soji
    Edahiro, Yoko
    Takei, Hiraku
    Yoo, Yongjin
    Choi, Murim
    Sunami, Yoshitaka
    Hironaka, Yumi
    Noguchi, Masaaki
    Koike, Michiaki
    Noda, Naohiro
    Ohsaka, Akimichi
    Komatsu, Norio
    HAEMATOLOGICA, 2015, 100 (02) : E46 - E48
  • [29] Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation
    Bang, Soo-Mee
    Lee, Jong-Seok
    Ahn, Jeong Yeal
    Lee, Jae Hoon
    Hyun, Myung Soo
    Kim, Bong Seog
    Park, Moo Rim
    Chi, Hyun-Sook
    Kim, Ho Young
    Kim, Hyo Jung
    Lee, Moon Hee
    Kim, Hwak
    Won, Jong Ho
    Yoon, Hwi Joong
    Oh, Do-yeun
    Nam, Eun-Mi
    Bae, Sung Hwa
    Kim, Byoung-Kook
    THROMBOSIS AND HAEMOSTASIS, 2009, 101 (03) : 547 - 551
  • [30] Clinical outcomes of patients with JAK2, CALR and MPL positive myeloproliferative neoplasms
    Komic, H.
    Islamagic, E.
    Kurtovic, S.
    Burekovic, A.
    Uzunovic, A.
    Kurtovic-Kozaric, A.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1841 - 1842
12345